VRNA Verona Pharma ADS

Verona Pharma Announces December 2024 Investor Conference Participation

Verona Pharma Announces December 2024 Investor Conference Participation

LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:

Piper Sandler 36th Annual Healthcare Conference

Date: Tuesday, December 3, 2024

Time: 12:00 p.m. ET / 5:00 p.m. GMT

Location: New York, NY

7th Annual Evercore HealthCONx Conference

Date: Wednesday, December 4, 2024

Time: 3:00 p.m. ET / 8:00 p.m. GMT

Location: Miami, FL

A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, .

For further information please contact:

  
Verona Pharma plcTel:
Victoria Stewart, Senior Director of Investor

Relations and Communications
Argot Partners

(US Investor Enquiries)		Tel:

Ten Bridge Communications

International / US Media Enquiries		Tel:

Wendy Ryan 



About Verona Pharma

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit .



EN
19/11/2024

Underlying

VRNAVerona Pharma ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Verona Pharma ADS

 PRESS RELEASE
Free
VRNA Verona Pharma A...

Shareholders of Verona Pharma Approve Proposed Acquisition by Merck

Shareholders of Verona Pharma Approve Proposed Acquisition by Merck Transaction expected to close on October 7, 2025 LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by Merck & Co., Inc. (NYSE: MRK) (“Merck”) through a wholly owned subsidiary or a nominee, today announced that its shareholders have approved the proposal for Merck to acquire Verona Pharma for $107 ...

September 24, 2025 1 EN
 PRESS RELEASE
Free
VRNA Verona Pharma A...

Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE St...

Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025 Posters support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces two posters on additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonar...

September 16, 2025 1 EN
Free Trial
VRNA Verona Pharma A...

Verona Pharma: 2 directors

Two Directors at Verona Pharma sold 100,000 shares at 91.207USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

VRNA VERONA PHARMA ADS
06/16/25 June 16, 2025 1 EN
 PRESS RELEASE
Free
VRNA Verona Pharma A...

Verona Pharma Announces June 2025 Investor Conference Participation

Verona Pharma Announces June 2025 Investor Conference Participation LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:05 a.m. ET / 4:05 p.m. BSTLocation: New York, NY Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Monday, June 9, 2025Time: 2:40 p.m. ET / 7:40 p.m. BSTLocation: Miami, FL A webcast of each conferenc...

May 21, 2025 1 EN
 PRESS RELEASE
Free
VRNA Verona Pharma A...

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies...

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”),...

May 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch